← Back to Search

Genetically-Informed RiskProfile for Tobacco Use Disorder

N/A

Waitlist Available

Led By Alex T Ramsey, Ph.D.

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Awards & highlights

Study Summary

This trial will test a new way to help people quit smoking that is tailored to their genetic risk.

Eligible Conditions

Tobacco Use Disorder
Smoking Cessation
Quitting Smoking

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Number of Cigarettes Smoked Per Day

Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days

Secondary outcome measures

Change in Perceived Benefits of Cessation

Change in Perceived Disease Risk

Change in Perceived Value of Cessation Treatments

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Genetically-Informed RiskProfileExperimental Treatment1 Intervention

Group II: Brief Cessation AdviceActive Control1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Genetically-Informed RiskProfile

2021

N/A

~150

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor

1,935 Previous Clinical Trials

2,299,725 Total Patients Enrolled

3 Trials studying Tobacco Use Disorder

3,384 Patients Enrolled for Tobacco Use Disorder

National Institute on Drug Abuse (NIDA)NIH

2,468 Previous Clinical Trials

2,619,200 Total Patients Enrolled

271 Trials studying Tobacco Use Disorder

48,919 Patients Enrolled for Tobacco Use Disorder

Alex T Ramsey, Ph.D.Principal InvestigatorWashington University School of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is admission to this clinical research still open for volunteers?

"The data accessible on clinicaltrials.gov indicates that this investigation is not presently recruiting patients. Initially posted in March 2021, it was last modified in July 2022. Although this trial isn't actively sourcing participants at present, there are currently 611 other studies with open enrollment slots."

Answered by AI

What are the fundamental goals of this research endeavor?

"The prime focus of this research endeavour is to measure the alteration in usage of smoking cessation pharmaceuticals over Baseline, just before intervention administration, 30-day post-intervention observation and 6-month follow up. Secondary objectives include evaluating personal relevance of the treatment, gauging any shift in readiness for quitting smoking (Stage of Change) as well as monitoring changes in perceived benefits of abstinence from tobacco products."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Implementation of Genomics in Substance Use Disorder Treatment

2021. "Implementation of Genomics in Substance Use Disorder Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04768114.